valproic acid has been researched along with Carcinoma, Renal Cell in 14 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Carcinoma, Renal Cell: A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clear cell renal cell carcinoma (ccRCC) is one of the most common cancers in the world." | 1.56 | ID1 As a Prognostic Biomarker and Promising Drug Target Plays a Pivotal Role in Deterioration of Clear Cell Renal Cell Carcinoma. ( Gu, Y; Li, Q; Ni, Y; Qiu, X, 2020) |
| "Metformin (Met) is a widely available diabetic drug and shows suppressed effects on renal cell carcinoma (RCC) metabolism and proliferation." | 1.48 | Valproic acid sensitizes metformin-resistant human renal cell carcinoma cells by upregulating H3 acetylation and EMT reversal. ( Chen, Y; Huang, Z; Lan, X; Li, L; Lu, G; Mao, S; Wei, M; Xia, Q; Zhao, M; Zhao, Y, 2018) |
| "Everolimus resistance was accompanied by significant increases in the percentage of G2/M-phase cells and in the IC50." | 1.40 | HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A. ( Bartsch, G; Blaheta, RA; Haferkamp, A; Harder, S; Juengel, E; Makarevi, J; Mani, J; Natsheh, I; Nelson, K; Nowaz, S; Reiter, M; Tsaur, I; Werner, I, 2014) |
| " We assume that chronic use of an HDAC-inhibitor is associated with (re)-activation of Akt, which may be involved in resistance development." | 1.39 | Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo. ( Bartsch, G; Blaheta, RA; Haferkamp, A; Juengel, E; Makarević, J; Nelson, K; Tsaur, I, 2013) |
| " VPA was also combined with low dosed interferon-alpha (IFN-alpha) and the efficacy of the combination therapy, as opposed to VPA monotherapy, was compared." | 1.35 | Valproic acid blocks adhesion of renal cell carcinoma cells to endothelium and extracellular matrix. ( Blaheta, RA; Hintereder, G; Hudak, L; Jonas, D; Jones, J; Juengel, E; Mickuckyte, A; Wedel, S, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 10 (71.43) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Qiu, X | 1 |
| Gu, Y | 1 |
| Ni, Y | 1 |
| Li, Q | 1 |
| Mao, S | 2 |
| Lu, G | 2 |
| Lan, X | 2 |
| Yuan, C | 1 |
| Jiang, W | 1 |
| Chen, Y | 2 |
| Jin, X | 1 |
| Xia, Q | 2 |
| Xi, W | 1 |
| Chen, X | 1 |
| Sun, J | 1 |
| Wang, W | 1 |
| Huo, Y | 1 |
| Zheng, G | 1 |
| Wu, J | 1 |
| Li, Y | 1 |
| Yang, A | 1 |
| Wang, T | 1 |
| Wei, M | 1 |
| Li, L | 1 |
| Huang, Z | 1 |
| Zhao, M | 1 |
| Zhao, Y | 1 |
| Ozerdem, A | 1 |
| Ceylan, D | 1 |
| Targıtay, B | 1 |
| Juengel, E | 7 |
| Nowaz, S | 1 |
| Makarevi, J | 1 |
| Natsheh, I | 1 |
| Werner, I | 1 |
| Nelson, K | 2 |
| Reiter, M | 1 |
| Tsaur, I | 3 |
| Mani, J | 1 |
| Harder, S | 1 |
| Bartsch, G | 3 |
| Haferkamp, A | 3 |
| Blaheta, RA | 8 |
| Zhang, X | 2 |
| Huang, T | 1 |
| Geng, J | 1 |
| Liu, M | 1 |
| Zheng, J | 1 |
| Jones, J | 5 |
| Mickuckyte, A | 3 |
| Hudak, L | 4 |
| Wedel, S | 2 |
| Jonas, D | 5 |
| Hintereder, G | 1 |
| Engler, J | 1 |
| Bhasin, M | 1 |
| Libermann, T | 1 |
| Barth, S | 1 |
| Michaelis, M | 1 |
| Cinatl, J | 1 |
| Dauselt, A | 1 |
| Makarević, J | 3 |
| Wiesner, C | 1 |
| Oertl, A | 1 |
| Relja, B | 1 |
| Weich, E | 1 |
| Höfler, S | 1 |
| Bratzke, H | 1 |
| Baer, PC | 1 |
1 review available for valproic acid and Carcinoma, Renal Cell
| Article | Year |
|---|---|
The Relationship Between Lithium and Cancer Proliferation: A Case-Based Review of the Literature.
Topics: Angiomyolipoma; Antimanic Agents; Apoptosis; Bipolar Disorder; Carcinoma, Renal Cell; Cell Prolifera | 2018 |
13 other studies available for valproic acid and Carcinoma, Renal Cell
| Article | Year |
|---|---|
ID1 As a Prognostic Biomarker and Promising Drug Target Plays a Pivotal Role in Deterioration of Clear Cell Renal Cell Carcinoma.
Topics: Biomarkers, Tumor; Carcinoma, Renal Cell; DNA, Neoplasm; Down-Regulation; Drug Delivery Systems; Gen | 2020 |
Valproic acid inhibits epithelial‑mesenchymal transition in renal cell carcinoma by decreasing SMAD4 expression.
Topics: Cadherins; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition | 2017 |
Combined Treatment with Valproic Acid and 5-Aza-2'-Deoxycytidine Synergistically Inhibits Human Clear Cell Renal Cell Carcinoma Growth and Migration.
Topics: Apoptosis; Azacitidine; Carcinoma, Renal Cell; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Moveme | 2018 |
Valproic acid sensitizes metformin-resistant human renal cell carcinoma cells by upregulating H3 acetylation and EMT reversal.
Topics: Acetylation; Apoptosis; Carcinoma, Renal Cell; Cell Cycle; Cell Line, Tumor; Cell Movement; Drug Res | 2018 |
HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A.
Topics: Carcinoma, Renal Cell; Cell Line, Tumor; Cyclin A; Cyclin-Dependent Kinase 2; Drug Resistance, Neopl | 2014 |
Combination of metformin and valproic acid synergistically induces cell cycle arrest and apoptosis in clear cell renal cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Renal Cell; Cell Cycle Checkpo | 2015 |
The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo.
Topics: Animals; Carcinoma, Renal Cell; Cell Division; Histone Deacetylase Inhibitors; Humans; Kidney Neopla | 2009 |
Valproic acid blocks adhesion of renal cell carcinoma cells to endothelium and extracellular matrix.
Topics: Carcinoma, Renal Cell; Cell Adhesion; Cell Line, Tumor; Endothelium; Extracellular Matrix; Humans; K | 2009 |
Effects of combined valproic acid and the epidermal growth factor/vascular endothelial growth factor receptor tyrosine kinase inhibitor AEE788 on renal cell carcinoma cell lines in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Renal Cell; Cell Adhes | 2010 |
Alterations of the gene expression profile in renal cell carcinoma after treatment with the histone deacetylase-inhibitor valproic acid and interferon-alpha.
Topics: Carcinoma, Renal Cell; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Surv | 2011 |
Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells.
Topics: Acetylation; Apoptosis; Carcinoma, Renal Cell; Cell Cycle; Cell Differentiation; Cell Line, Tumor; C | 2012 |
Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo.
Topics: Acetylation; Animals; Carcinoma, Renal Cell; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinases; | 2013 |
Altered expression of beta1 integrins in renal carcinoma cell lines exposed to the differentiation inducer valproic acid.
Topics: Carcinoma, Renal Cell; Cell Adhesion; Cell Differentiation; Cell Line, Tumor; Cells, Cultured; Disea | 2006 |